The antimicrobial susceptibility testing industry is experiencing notable advancements driven by rising infectious diseases and the urgent need for effective antibiotic stewardship globally. Innovations in rapid diagnostics and increasing adoption in clinical and research settings highlight the growing importance of this sector. These dynamics are shaping the antimicrobial susceptibility testing market size and propelling overall market growth.
Market Size and Overview
The global antimicrobial susceptibility testing market size is estimated to be valued at USD 4.21 billion in 2025 and is expected to reach USD 6.72 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.9% from 2025 to 2032. Antimicrobial Susceptibility Testing Market Growth is driven by enhanced demand for rapid and precise diagnostics that support antimicrobial resistance (AMR) management efforts, coupled with expanding healthcare infrastructure in emerging economies. The industry size is further buoyed by increasing investments in research and development activities targeting novel testing methodologies and platforms.
Market Segments
The antimicrobial susceptibility testing market is broadly segmented into Product Type, Application, and End User categories.
- Product Type includes Manual, Automated Systems, and Consumables. Automated systems dominate the landscape due to superior accuracy and turnaround time; for instance, Thermo Fisher’s automated susceptibility platforms reported revenue increases exceeding 15% in 2024. Meanwhile, manual testing remains the fastest-growing sub-segment in resource-limited regions, reflecting expanding market opportunities.
- Application covers Clinical Diagnostics, Pharmaceutical Research, and Food Safety Testing. Clinical diagnostics leads the sector, accounting for the majority of the market size, whereas pharmaceutical research is the fastest-growing sub-segment as personalized medicine drives demand for detailed antibiotic profiling.
- End Users include Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Pharmaceutical Companies. Hospitals and diagnostic labs remain the dominant segment in market revenue, with academic research institutes emerging rapidly, fuelled by increasing surveillance programs and AMR studies in 2024–2025.
Market Drivers
One key market driver is the global emphasis on combating antimicrobial resistance, recognized as a critical public health threat. In 2024, several governments and health organizations enacted stricter policies mandating routine antimicrobial susceptibility testing before antibiotic prescriptions, accelerating market growth. For example, enhanced regulatory frameworks in Europe and North America increased antimicrobial susceptibility testing volume by 10–12% year-over-year. Advances in rapid testing technologies, coupled with growing awareness about infection control, continue to magnify market opportunities, effectively steering the market dynamics.
Segment Analysis: Product Type
Automated systems maintain dominance in product type segments due to their operational efficiency and scalability. In 2025, automated instruments contributed a significant proportion of antimicrobial susceptibility testing market revenue, supported by case studies demonstrating up to 30% reduction in diagnostic turnaround time in leading hospitals using advanced automated platforms. The fastest-growing product sub-segment is manual testing, particularly in emerging markets, due to lower investment costs and applicability in decentralized healthcare settings where automated infrastructure is limited.
Consumer Behaviour Insights
Recent consumer behaviour trends indicate rising preference for digital integration in susceptibility testing workflows, emphasizing connectivity to hospital information systems for real-time data access and analytics. Approximately 60% of diagnostic laboratories surveyed in 2024 adopted connected antimicrobial susceptibility testing systems to improve decision-making speed. Additionally, customization trends emerged, with end users seeking testing kits optimized for local pathogen profiles, reflecting heightened pricing sensitivity and quality differentiation. Sustainability preferences grew, illustrated by increased demand for eco-friendly consumables, which now account for nearly 20% of product portfolios among key suppliers.
Key Players
Prominent market companies include Thermo Fisher Scientific, bioMérieux, BD, Agilent Technologies, Bruker, Accelerate Diagnostics, Luminex, and others, constituting the core market players landscape. Strategic moves in 2024 and 2025 have involved new product launches focusing on rapid molecular testing, capacity expansion to meet rising demand, and regional penetration into Asia-Pacific and Latin America. Thermo Fisher’s expansion of automated susceptibility testing offerings in 2025 led to a reported 18% increase in market revenue within North American territories, illustrating effective market growth strategies.
Key Winning Strategies Adopted by Key Players
A notable winning strategy was Thermo Fisher’s 2025 launch of integrated AI-driven susceptibility testing platforms, significantly improving diagnostic accuracy and predictive analyses, resulting in a 25% improvement in clinician satisfaction scores. Another impactful approach was the deployment of turnkey laboratory solutions by select players combining both hardware and software facets, enhancing laboratory workflow efficiency and reducing testing times by over 20% in 2024. Additionally, strategic partnerships with regional healthcare providers enabled faster market access and customized product adaptation, driving substantial business growth in underserved markets.
FAQs
1. Who are the dominant players in the antimicrobial susceptibility testing market?
Key market players include Thermo Fisher Scientific, bioMérieux, BD, Agilent Technologies, and Bruker, among others. These companies are leading market growth through innovation, capacity expansion, and geographic diversification.
2. What will be the size of the antimicrobial susceptibility testing market in the coming years?
The market is projected to grow from USD 4.21 billion in 2025 to USD 6.72 billion by 2032, with a CAGR of 6.9%, reflecting robust market demand and technological advancements.
3. Which end user industry has the largest growth opportunity?
Hospitals and diagnostic laboratories offer the largest growth opportunities due to rising infection rates and increasing implementation of AMR surveillance programs globally.
4. How will market development trends evolve over the next five years?
Market trends point toward increasing adoption of automated and AI-integrated testing platforms, expansion into emerging markets, and growing preference for sustainable consumables.
5. What is the nature of the competitive landscape and challenges in the antimicrobial susceptibility testing market?
The competitive landscape is dynamic, with key players focusing on innovation and regional expansions. Challenges include price sensitivity in emerging markets and regulatory complexities affecting product approvals.
6. What go-to-market strategies are commonly adopted in the antimicrobial susceptibility testing market?
Common strategies encompass product innovation, strategic partnerships with healthcare providers, expansion of testing capabilities, and leveraging digital connectivity to enhance laboratory workflows.
Get more insights on, Antimicrobial Susceptibility Testing Market
Get This Report in Japanese Language: 抗菌薬感受性試験市場
Get This Report in Korean Language: 동물 모델 시장
Read More Articles Related to this Industry- Clinical Practices: Importance of Stethoscopes in Diagnosis by Fasting Academy
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment